Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma

Angela Ferrario, Karl F. von Tiehl, Natalie Rucker, Margaret A. Schwarz, Parkash S. Gill, and Charles J. Gomer

Clayton Center for Ocular Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027; [A. F., K. F. v. T., N. R., C. J. G.], and Departments of Pediatrics [C. J. G., M. A. S.], Radiation Oncology [C. J. G.], Medicine [P. S. G.], Pathology [P. S. G.], and Surgery [M. A. S.], Keck School of Medicine, University of Southern California, Los Angeles, California 90033

Abstract

Photodynamic therapy (PDT) is a promising cancer treatment that induces localized tumor destruction via the photochemical generation of cytotoxic singlet oxygen. PDT-mediated oxidative stress elicits direct tumor cell damage as well as microvascular injury within exposed tumors. Reduction in vascular perfusion associated with PDT-mediated microvascular injury produces tumor tissue hypoxia. Using a transplantable BA mouse mammary carcinoma, we show that Photofofin-mediated PDT induced expression of the hypoxia-inducible factor-1α (HIF-1α) subunit of the heterodimeric HIF-1 transcription factor and also increased protein levels of the HIF-1 target gene, vascular endothelial growth factor (VEGF), within treated tumors. HIF-1α and VEGF expression were also observed following tumor clamping, which was used as a positive control for inducing tissue hypoxia. PDT treatment of BA tumor cells grown in culture resulted in a small increase in VEGF expression above basal levels, indicating that PDT-mediated hypoxia and oxidative stress could both be involved in the overexpression of VEGF. The tumor-bearing mice treated with combined antiangiogenic therapy (IM862 or EMAP-II) and PDT had improved tumoricidal responses compared with individual treatments. We also demonstrated that PDT-induced VEGF expression in tumors decreased when either IM862 or EMAP-II was included in the PDT treatment protocol. Our results indicate that combination procedures using antiangiogenic treatments can improve the therapeutic effectiveness of PDT.

Introduction

PDT involves treating solid malignancies with tissue-penetrating laser light following the systemic administration of a tumor localizing photosensitizer (1). Properties of photosensitizer localization in tumor tissue and photochemical generation of reactive oxygen species are combined with precise delivery of laser-generated light to produce a treatment offering local tumoricidal activity (2, 3). The porphyrin photosensitizer PH recently received Food and Drug Administration approval for PDT treatment of esophageal and endobronchial carcinomas (1). PDT is also undergoing ongoing clinical evaluation for the treatment of bladder, head and neck, brain, intrathoracic, and skin malignancies (1). PDT targets include tumor cells, tumor microvasculature, inflammatory cells, and immune host cells (1–3). Vascular effects induced by PH-mediated PDT include perfusion changes, vessel constriction, macromolecular vessel leakage, leukocyte adhesion, and thrombus formation (1, 4). These effects appear to be linked to platelet activation and release of thromboxane (5). Microvasculature damage is readily observed histologically following PDT and leads to a significant decrease in blood flow as well as severe and persistent tumor tissue hypoxia (6, 7). Rapid and substantial reductions in tissue oxygenation can also occur during illumination by direct utilization of oxygen during the photochemical generation of reactive oxygen species (7, 8).

Tissue hypoxia induces a plethora of molecular and physiological responses, including an adaptive response associated with gene activation (9). A primary step in hypoxia-mediated gene activation is the formation of the HIF-1 transcription factor complex (9, 10). HIF-1 is a heterodimeric complex of two helix-loop-helix proteins, HIF-1β (ARNT) and HIF-1α (11). ARNT is constitutively expressed, whereas HIF-1α is rapidly degraded under normoxic conditions. Hypoxia induces the stabilization of the HIF-1α subunit, which in turn allows for the formation of the transcriptionally active protein complex (11, 12). A number of HIF-1-responsive genes have been identified, including VEGF, erythropoietin, and glucose transporter-1 (11). VEGF, also called vascular permeability factor, is an endothelial cell-specific mitogen involved in the induction and maintenance of the neovascularization in solid tumors (11, 13). VEGF expression increases in tumor tissue under hypoxia as a result of both transcriptional activation and increased stabilization (11, 14).

In the current study, we examined whether PDT-induced microvascular damage and the resulting hypoxia could serve as activators of molecular events leading to the increased expression of VEGF within treated tumor tissue. We also determined whether antiangiogenic compounds, which counter the actions of VEGF, could improve PDT tumor responsiveness. Our results document that PH-mediated PDT induces expression of HIF-1α and the transcription factor’s target gene, VEGF, in a transplanted mouse mammary carcinoma. We also document enhanced tumoricidal activity when PDT is combined with antiangiogenic therapy.

Materials and Methods

Drugs and Reagents.

The photosensitizer Photofrin porfimer sodium was a gift from QLT PhotoTherapeutics, Inc. (Vancouver, British Columbia, Canada) and was dissolved in 5% dextrose in water to make a 2.5 mg/ml stock solution. Recombinant EMAP-II was prepared as described previously (15). A working solution at 10 μg/ml was prepared in PBS containing 0.1% BSA. IM862 was obtained from Cytran Inc. (Kirkland, WA) and was dissolved in saline to make a 5 mg/ml working solution (16). CoCl2 was obtained from Sigma Chemical Co. (St. Louis, MO), and a 10 mM stock solution was prepared in water.
Cells and in Vivo Tumor Model. BA mouse mammary carcinoma cells (originally obtained from the NIH tumor bank) were used in all in vitro and in vivo experiments (17). Cells were grown as a monolayer in RPMI 1640 supplemented with 10% FCS and antibiotics. The plating efficiency for the BA cells was 40–60%. s.c. BA mammary carcinomas were generated by trocar injection of 1-mm³ pieces of tumor to the hind right flank of 8- to 12-week-old female C3H/HeJ mice (17).

In Vitro and in Vivo Treatment Protocols. In vitro photosensitization protocols involved seeding cells into plastic Petri dishes and incubating overnight in complete growth medium to allow for cell attachment. PDT treatments included incubating cells in the dark at 37°C for 16 h with PH (25 μg/ml) in medium containing 5% FCS. Cells were then incubated for an additional 30 min in growth medium containing 10% FCS, rinsed in medium without serum, and exposed to red light (570–650 nm) generated by a parallel series of red Mylar-filtered 30 W fluorescent bulbs and delivered at a dose rate of 0.35 mW/cm². In specified experiments, cells were incubated with CoCl₂ (100 μM) in growth medium containing 5% FCS for 16 h. Treated cells were then re-fed with complete growth medium and incubated in the dark at 37°C until collected for analysis of VEGF secretion into the culture media. In vivo PDT tumor treatments were performed as reported previously on tumors measuring 6–7 mm in diameter (17). Briefly, PDT procedures included an i.v. injection of PH (5 mg/kg) followed 24 h later with non-thermal laser tumor irradiation using an argon-pumped dye laser emitting red light at 630 nm. A light dose rate of 75 mW/cm² and a total light dose of 200 J/cm² were used for all in vivo PDT treatments. After treatment, tumors were measured three times per week. Cures were defined as being disease free for at least 40 days after PDT (17). Antiangiogenic treatment was performed using either EMAP-II or IM862. Each compound was administered as daily i.p. injections for 10 consecutive days starting 1 h prior to PDT light treatment. Individual IM862 doses were 25 mg/kg, and individual EMAP-II doses were 50 μg/kg. Tumor tissue hypoxia was induced in selected experiments by clamping lesions for 45 min.

Western Blot Analysis. Tumors were collected at various times after treatment, homogenized with a Polytron in 1× reporter lysis buffer (Promega, Madison, WI), and evaluated for protein expression as described previously (18). Briefly, protein samples (30 μg) were size-separated on 10% (for HIF-1α) or 12.5% (for VEGF) discontinuous polyacrylamide gels and transferred overnight to nitrocellulose membranes. Filters were blocked for 1 h with 5% nonfat milk and then incubated for 2 h with either a mouse monoclonal anti-HIF-1α antibody (clone 54; Transduction Laboratories, Lexington, KY), a rabbit polyclonal anti-VEGF antibody (no. sc-507; Santa Cruz Biotechnology, Santa Cruz, CA), or a mouse monoclonal antiactin antibody (clone C-4; ICN, Aurora, OH). Filters were then incubated with either an antimouse or antirabbit peroxidase conjugate (Sigma), and the resulting complexes were visualized by enhanced chemiluminescence autoradiography (Amersham Life Science, Chicago, IL).

ELISA Assays. A Quantikine M mouse VEGF ELISA kit (R&D Systems, Minneapolis, MN) was used to quantify VEGF levels in cell culture media as well as in tumor extracts from control and treated mice. Results were normalized to protein concentrations from tumor tissue or cell lysates.

Statistics. Statistical analysis was performed using a two-tailed Student’s t test to analyze VEGF levels and the χ² test for evaluation of tumor cure rates.

Results and Discussion

PDT continues to show promise in the treatment of a variety of malignant and nonmalignant disorders (1, 19). The use of PDT for advanced esophageal tumors offers prolonged tumor responses compared with standard Nd-YAG laser ablation treatments. Extended tumor responses are also observed in advanced non-small cell lung cancer patients treated with PDT compared with Nd-YAG laser ablation. Likewise, PDT applications continue to be encouraging for early stage lung cancer, brain cancers, head and neck cancers, and for nononcological disorders such as age-related macular degeneration (1, 19). Nevertheless, recurrences are observed after PDT, and methods to improve the therapeutic efficacy of this procedure are needed. Multiple physiological, biophysical, and/or pharmacological variables may account for recurrences after PDT (2, 3). Nonuniform distribution of photosensitizers within tumor tissue, inadequate light distribution, photosensitizer photobleaching, and treatment-induced oxy-
vascularity (20). Our results suggest that PDT may be functioning as a mediator of tumor angiogenesis and tumor recurrence by enhancing expression of VEGF within the treated tumor mass (14).

We next examined whether in vitro PDT of BA mammary carcinoma cells could also induce expression of VEGF. Fig. 2 shows VEGF levels collected from culture media at various time intervals for control and treatment conditions. Exposure to CoCl₂ served as a statistically significant positive control because exposure to this divalent metal induces cellular VEGF expression (11). A 210 J/m² PDT dose resulted in a modest increase in VEGF levels when measured 24 h after treatment. The PDT doses (210 and 420 J/m²) and CoCl₂ treatment produced clonogenic survival levels ranging from 33% to 96%. The in vitro PDT conditions would be expected to involve singlet oxygen-mediated oxidative stress but not induced hypoxia. These results suggest that the increase in VEGF expression observed in tumors after in vivo PDT may be associated with treatment-induced hypoxia and to a lesser extent with treatment-induced oxidative stress. Exposure of various mouse and human tumor cells to ionizing radiation and exposure of rat endothelial cells to hydrogen peroxide can up-regulate VEGF expression (20, 21). Additional studies will be required to determine similarities and differences in VEGF induction for various types of oxidative stress.

A growing number of reports have indicated that antiangiogenic agents can enhance the tumoricidal effectiveness of chemotherapy and radiation treatments (20, 22, 23). We next examined whether antiangiogenic treatments, using either EMAP-II or IM862, could enhance the tumoricidal action of PDT. EMAP-II is a single chain polypeptide that inhibits tumor growth and has antiangiogenic activity (15). EMAP-II induces apoptosis in growing capillary endothelial cells in both a time- and dose-dependent manner. EMAP-II also prevents vessel ingrowth in experimental angiogenesis models and in primary tumors. Interestingly, EMAP-II does not induce toxicity in normal organs. IM862 is a dipeptide of L-glutamyl-L-tryptophan that was initially isolated from the thymus (16). Preclinical studies have shown that the dipeptide inhibits angiogenesis in choroidalantico membrane assays and inhibits VEGF production in monocytic lineage cells (4). IM862 also inhibits tumor growth in xenograft models but has no direct cytotoxic effect on tumor cells. IM862 mediates these effects by...
inhibiting production of VEGF and by activating natural killer cells. Intranasal administration of IM862 exhibits antitumor activity in patients with AIDS-associated Kaposi’s sarcoma (16). IM862 also appears to be safe and well tolerated when delivered over prolonged time periods. A PDT procedure that produced a moderate cure rate alone was used to measure positive or negative changes in tumor response when a single PDT treatment was combined with daily injections of EMAP-II or IM862 for 10 days (17). Fig. 3 shows that antiangiogenic treatment statistically enhanced ($P < 0.05$) the tumorici-
cal action of PDT as measured by tumor cures. Specifically, the 200
J/cm$^2$ PDT dose alone produced a 39% cure rate, whereas PDT plus
EMAP-II or IM862 produced tumor cures of 89 and 78%, respec-
tively. The antiangiogenic treatments alone did not produce any tumor
cures or tumor regression and only slightly modified tumor growth
parameters.

Finally, we examined whether the antiangiogenic derivatives used in
this study modulated PDT-induced VEGF levels in treated tumors. The in vivo PDT dose delivered to tumors (200 J/cm$^2$) induced rapid
and severe tissue necrosis. Therefore, tumor samples were only col-
cected 24 h after PDT. This timeframe allowed for two antiangiogenic
drug doses (1 h prior to light treatment and 1 h prior to sacrifice). Fig.
4 shows a decrease in VEGF levels, measured by ELISA, in tumors
with PDT combined with EMAP-II or IM862 compared with tumors
with PDT alone. These results were obtained after only two
of either EMAP-II or IM862. Nevertheless, a statistically
significant decrease ($P < 0.01$) in PDT-induced VEGF levels was
observed when EMAP-II was included in the treatment protocol. It
is likely the 10 daily doses of EMAP-II or IM862 used in the PDT tumor
treatment experiments would further attenuate VEGF levels.

In summary, we demonstrate that antiangiogenic treatments can
potentiate PDT responsiveness. This result may involve attenuating
the angiogenic actions of VEGF, which was observed to increase in
PDT-treated tumors. Optimization of antiangiogenic parameters
as well as an examination of various methods to block angiogenesis
are being performed at present. The minimal systemic toxicity associated
with antiangiogenic therapy suggests that these procedures should
be compatible with clinical PDT and may provide an efficient strategy
for selectively enhancing PDT tumor responsiveness. It will also be of
clinical interest to determine whether antiangiogenic treatments can
enhance PDT procedures for age-related macular degeneration be-
cause this pathology is marked by neovascularization (19).

Acknowledgments

We thank QLT PhotoTherapeutics, Inc. (Vancouver, British Columbia,
Canada) for the generous gift of Photofrin, and Cytran Inc. (Kirkland, WA) for
the generous gift of IM862.

References

1. Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M.,
1998.

2. Henderson, B. W., and Dougherty, T. J. How does photodynamic therapy work?


microvascular damage in photodynamic therapy: the effect of treatment on vessel
constriction, permeability, and leukocyte adhesion. Cancer Res., 52: 4914–4921,

5. Fingar, V. H., Wieman, T. J., and Haydon, P. S. The effects of thrombocytopenia on
vessel stasis and micromass flow at a photodynamic therapy using Photofrin.

6. van Geel, I. P. J., Oppelaar, H., Rijken, P. J. F. J., Berndsen, H. J. J. A., Hagemeier,
and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br. J. Cancer, 75:
288–293, 1996.

during and after photodynamic therapy in vivo: effects of fluence rate. Br. J. Cancer,

8. Foster, T. H., Murant, R. S., Byrant, R. G., Knox, R. S., Gibson, S. L., and Hilf, R.

9. Ratcliffe, P. J., O’Rourke, J. F., Maxwell, P. H., and Fugh, C. W. Oxygen sensing,
inducible NO synthase, and the regulation of mammalian gene expression. J. Exp.

10. Wang, G. L., and Semenza, G. L. General involvement of hypoxia-inducible factor in
transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA, 90: 4303–4308,
1993.

Activation of vascular endothelial growth factor gene transcription by hypoxia-

12. Huang, L. E., Gu, J., Schau, M., and Bunn, H. F. Regulation of hypoxia-inducible
factor 1alpha is mediated by an oxygen dependent degradation domain via the ubiquitin

endothelial cell permeability factor and the regulation of mammalian gene expression. J. Exp.

14. Schwarz, M. A., Kandel, J., Brett, J., Li, J., Hayward, J., Schwarz, R. E., Chappey, O.,
polypeptide II, a novel antimicrobial protein that suppresses primary and metastatic
malignant stromal tumor growth and induces apoptosis in growing endothelial cells. J. Exp.

induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.),

Barbazetto, I., Zografos, L., Piguet, B., Lane, A. M., Birmgruber, R., van
den Berg, H., Strong, A., Manjuris, U., Gray, T., Pradini, M., Bressler, N. M.,
and Gragoudas, E. S. Photodynamic therapy with verteporfin for choroidal neovasculari-
cation caused by age-related macular degeneration: results of a single treatment in a

Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and
Weichselbaum, R. R. Blockade of the vascular endothelial growth factor stress
response increases the antitumor effects of ionizing radiation. Cancer Res., 59:

18. Chua, C. C., Hamdy, R. C., and Chua, B. H. Upregulation of vascular endothelial
growth factor by H$_2$O$_2$ in rat heart endothelial cells. Free Radic. Biol. Med., 25:

cytotoxic cancer therapies against primary and metastatic disease. Cancer Res., 52:

K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme,
V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiotatin
Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma

Angela Ferrario, Karl F. von Tiehl, Natalie Rucker, et al.

Cancer Res 2000;60:4066-4069.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/15/4066

Cited articles
This article cites 22 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/15/4066.full#ref-list-1

Citing articles
This article has been cited by 17 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/60/15/4066.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/60/15/4066.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.